CASTLE BIOSCIENCES INC
CSTLDecisionDx-UM is a prognostic test that accurately determines the metastatic risk associated with ocular melanoma tumors of the eye. Ocular melanoma is a term commonly used to describe tumors of the uveal tract such as uveal melanoma, choroidal melanoma, ciliary body melanoma, and iris melanoma. The DecisionDx-UM test was clinically validated on these tumors of the uveal tract. DecisionDx-UM assesses the gene expression profile (GEP) of a subset of genes which are differentially expressed in primary tumor cells compared to cells that have undergone transformation to a metastatic phenotype.
Drugs in Pipeline
6
Phase 3 Programs
4
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
D-Fi
Dystrophic Epidermolysis Bullosa
Autologous Human Fibroblast (azficel-T)
Bilateral Nasolabial Fold Wrinkles
FCX-007 (dabocemagene autoficel; see below for FCX-007 description)
Recessive Dystrophic Epidermolysis Bullosa
Autologous Human Fibroblasts (azficel-T)
Acne Scarring of the Face
Azficel-T (autologous fibroblasts)
Dysphonia Resulting From Vocal Fold Scarring
diacerein 1% ointment
Epidermolysis Bullosa
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
D-Fi | Phase 3 | Dystrophic Epidermolysis Bullosa | - | - |
Autologous Human Fibroblast (azficel-T) | Phase 3 | Bilateral Nasolabial Fold Wrinkles | - | - |
FCX-007 (dabocemagene autoficel; see below for FCX-007 description) | Phase 3 | Recessive Dystrophic Epidermolysis Bullosa | - | - |
Autologous Human Fibroblasts (azficel-T) | Phase 3 | Acne Scarring of the Face | - | - |
Azficel-T (autologous fibroblasts) | Phase 2 | Dysphonia Resulting From Vocal Fold Scarring | - | - |
diacerein 1% ointment | Phase 2 | Epidermolysis Bullosa | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CASTLE BIOSCIENCES INC's drug pipeline?→
CatalystAlert tracks 6 drug candidates in CASTLE BIOSCIENCES INC's (CSTL) pipeline across Phase 3, Phase 2. Its lead program is D-Fi (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CASTLE BIOSCIENCES INC's next FDA catalyst?→
CASTLE BIOSCIENCES INC's (CSTL) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CSTL biotech catalysts?→
Add CSTL to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CASTLE BIOSCIENCES INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.